Evidence map›Paper›PMID 25127858›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.

Sergey V Ryzhov, Michael W Pickup, Anna Chytil, Agnieszka E Gorska, Qinkun Zhang, Philip Owens, Igor Feoktistov, Harold L Moses, Sergey V Novitskiy

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 117 citations in OpenAlex.

  1. Article
  2. Enhanced antitumor efficacy of combined targeting of adenosine ACancer immunology, immunotherapy : CII · 2026
    Article
  3. Targeting CD39 as a Therapeutic for Cancer Immunotherapy.Expert reviews in molecular medicine · 2026
    Review
  4. Review
  5. Review
  6. Targeting Myeloid Cells for Cancer Immunotherapy.Cancer immunology research · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Impact of the selective A2British journal of cancer · 2022
    Article
  19. Review
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sergey V RyzhovCardiovascular Division, Department of Medicine, Vanderbilt University, Nashville, TN 37232; and sergey.v.novitskiy@vanderbilt.edu sergey.v.ryzhov@vanderbilt.edu.
Michael W PickupCancer Biology Department, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232.
Anna ChytilCancer Biology Department, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232.
Agnieszka E GorskaCancer Biology Department, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232.
Qinkun ZhangCardiovascular Division, Department of Medicine, Vanderbilt University, Nashville, TN 37232; and.
Philip OwensCancer Biology Department, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232.
Igor FeoktistovCardiovascular Division, Department of Medicine, Vanderbilt University, Nashville, TN 37232; and.
Harold L MosesCancer Biology Department, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232.
Sergey V NovitskiyCancer Biology Department, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232 sergey.v.novitskiy@vanderbilt.edu sergey.v.ryzhov@vanderbilt.edu.
Vanderbilt University · USVanderbilt-Ingram Cancer Center

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
TGF BETA SUPPRESSION AND PROMOTION OF MAMMARY CARCINOMASR01CA085492 · NCI · VANDERBILT UNIVERSITY · PI MOSES, HAROLD L, WEAVER, VALERIE MARIE · 2000 to 2015
$6.4M
TGF-beta in Mammary Development and TumorigenesisR01CA102162 · NCI · VANDERBILT UNIVERSITY · PI MOSES, HAROLD L · 2003 to 2013
$4.5M
Adenosine in Tumor-Host InteractionR01CA138923 · NCI · VANDERBILT UNIVERSITY · PI DIKOV, MIKHAIL M, FEOKTISTOV, IGOR · 2010 to 2014
$1.5M
Role of Adenosine Receptors in NeovascularizationR01HL095787 · NHLBI · VANDERBILT UNIVERSITY · PI FEOKTISTOV, IGOR · 2010 to 2013
$1.5M
NCI NIH HHS CA068485NCI NIH HHS CA085492NCI NIH HHS CA102162NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA085492NCI NIH HHS R01 CA102162NCI NIH HHS R01 CA138923NCI NIH HHS R01CA138923NHLBI NIH HHS R01 HL095787NHLBI NIH HHS R01HL095787
6 · The paper itself

Abstract

There is growing evidence that generation of adenosine from ATP, which is mediated by the CD39/CD73 enzyme pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells. We have previously shown that the deletion of the TGF-β type II receptor gene (Tgfbr2) expression in myeloid cells is associated with decreased tumor growth, suggesting protumorigenic effect of TGF-β signaling. In this study, we tested the hypothesis that TGF-β drives differentiation of myeloid-derived suppressor cells into protumorigenic terminally differentiated myeloid mononuclear cells (TDMMCs) characterized by high levels of cell-surface CD39/CD73 expression. We found that TDMMCs represent a major cell subpopulation expressing high levels of both CD39 and CD73 in the tumor microenvironment. In tumors isolated from mice with spontaneous tumor formation of mammary gland and conditional deletion of the type II TGF-β receptor in mammary epithelium, an increased level of TGF-β protein was associated with further increase in number of CD39(+)CD73(+) TDMMCs compared with MMTV-PyMT/TGFβRII(WT) control tumors with intact TGF-β signaling. Using genetic and pharmacological approaches, we demonstrated that the TGF-β signaling mediates maturation of myeloid-derived suppressor cells into TDMMCs with high levels of cell surface CD39/CD73 expression and adenosine-generating capacity. Disruption of TGF-β signaling in myeloid cells resulted in decreased accumulation of TDMMCs, expressing CD39 and CD73, and was accompanied by increased infiltration of T lymphocytes, reduced density of blood vessels, and diminished progression of both Lewis lung carcinoma and spontaneous mammary carcinomas. We propose that TGF-β signaling can directly induce the generation of CD39(+)CD73(+) TDMMCs, thus contributing to the immunosuppressive, proangiogenic, and tumor-promoting effects of this pleiotropic effector in the tumor microenvironment.

Indexed as

5'-NucleotidaseAnimalsAntigens, CDApyraseBone Marrow CellsCarcinoma, Lewis LungCell DifferentiationCell Line, TumorCell MovementFemaleMammary Glands, AnimalMammary Neoplasms, AnimalMiceMice, Inbred C57BLMice, KnockoutMyeloid Cells5'-NucleotidaseAntigens, CDApyraseCD39 antigenProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IITransforming Growth Factor betaVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID25127858
PMCPMC4157098
OpenAlexW1906804363

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.